Skip to content
Review Open access

Natural Products as GPCR-Targeting Antidepressant Candidates: Advances and Opportunities

Aug 2026 · Pharmaceuticals · Vol 19, pp. 1275 · 0 citations · 167 references
Medicine

TL;DR

The roles of major GPCR families implicated in depression are summarized and an updated overview of natural products that modulate these receptors is provided to support further investigation of natural product-derived GPCR modulators as potential leads for next-generation antidepressant development.

Abstract

Depression is a leading cause of disability worldwide, and currently available antidepressants are limited by delayed therapeutic onset, inadequate efficacy in some patients, and adverse effects. G protein-coupled receptors (GPCRs), the largest family of membrane receptors in the central nervous system, regulate neurotransmission, neuroplasticity, neuroinflammation, stress responses, and reward processing, and are therefore important targets for antidepressant drug development. Natural products are a rich source of structurally diverse bioactive compounds, many of which show antidepressant-like effects through the modulation of GPCR-mediated signaling pathways. In this narrative review, we summarize the roles of major GPCR families implicated in depression and provide an updated overview of natural products that modulate these receptors. We particularly emphasize receptor-specific mechanisms, downstream signaling networks, and the pharmacological actions of representative natural compounds. We also highlight emerging concepts in GPCR biology, including receptor heteromerization, signaling bias, and allosteric modulation, that may create new opportunities for antidepressant discovery. Finally, we discuss current challenges related to target validation, pharmacokinetics, and clinical translation. Collectively, these insights support further investigation of natural product-derived GPCR modulators as potential leads for next-generation antidepressant development.

Read PDF

Similar papers

Review Sep 2026

From Structural Resolution to Functional Elucidation: Research Progress of GPR158 as a Target for Antidepressant Drug Development.

Findings in this review reveal the potential regulatory function of GPR158 in the pathological process of depression and provide a solid theoretical basis for the development of antidepressant drugs targeting GPCRs, facilitating the subsequent development of more accurate and efficient antidepressant candidate drugs.

Wei Guan, Ya-Bin Zheng · 0 citations
Review Open access Sep 2026

Natural products as selective estrogen receptor modulators in depression-related disorders: Balancing antidepressant efficacy and safety.

Depression-related disorders remain major clinical challenges, and increasing evidence suggests that estrogen receptor (ER) signaling is involved in processes relevant to depression, including neuroinflammation, synaptic plasticity, neurotransmission, and stress regulation. Natural products and Traditional Chinese Medi...

Rong Chen, Jie Luo, Ke He et al. · 0 citations
Review Aug 2026

Therapeutic targeting of G protein-coupled receptors in central nervous system disorders: from novel mechanisms to precision pharmacology.

This review comprehensively examines the pathophysiological roles and therapeutic potential of GPCRs in major neurological and psychiatric disorders, including Parkinson's disease, Alzheimer's disease, multiple sclerosis, and depression, and highlights how dysregulated signaling through specific GPCRs contributes to di...

Chi-Cheng Zhou, Chunting Zhu, Xueying Wang et al. · 0 citations
Review Oct 2026

Molecular Pharmacology of Dopamine Receptors: Structure, Function, and Therapeutic Implications.

Dopamine receptors (DRs) mediate central and peripheral dopaminergic signaling and remain major therapeutic targets in movement disorders, psychiatric disease, and endocrine dysfunction. Despite decades of clinical use, existing DR-directed therapies still suffer from limited subtype selectivity, pathway-nonspecific en...

You-Wen Zhuang, H. E. Xu · 0 citations
Review Sep 2026

Targeting depression: Pharmacological mechanisms and therapeutic targets.

This review provides a systematic and critical evaluation of pharmacological mechanisms in depression and related therapeutic targets and proposes future directions for antidepressant drug development, including novel target discovery, rational multi-target design, and optimization of preclinical-to-clinical translatio...

Hui-Qin Wang, Shi-Fen Dong, Suo Liu et al. · 0 citations
Review Aug 2026

Thiazole-based Small Molecules as Potential Anti-Alzheimer's Agents: SAR and Mechanistic Insights.

This research highlights the feasibility of using thiazole-derived AChE, BuChE, MAO-B, and amyloid-β inhibitors as scaffold pharmacophores for developing novel drugs to treat Alzheimer's disease and provides vital guidance on the development of future drugs.

Geetanjali Chaudhary, Deepika Paliwal, Aman Thakur et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.